CoChat

Dysglycemia screening with oral glucose tolerance test in adolescents with polycystic ovary syndrome and relationship with obesity

Open access
Gupta, Jyotsna, Antal, Zoltan, Mauer, Elizabeth, Gerber, Linda M., An, Anjile, Censani, Marisa · 2022 · BMC Endocrine Disorders

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 7 of the 20 sources its claims cite were checked for support.

Abstract

Background: Adolescents with polycystic ovary syndrome (PCOS) are at increased risk of impaired glucose tolerance (IGT) and type 2 diabetes mellitus. The aim of this study is to evaluate dysglycemia and biochemical differences based on BMI status and assess the prognostic ability of elevated hemoglobin A1c (HbA1c) in predicting an abnormal 2 hour oral glucose tolerance test (OGTT). Methods: Retrospective cohort of female patients aged 11-18 years who underwent 75-g OGTT and were evaluated for PCOS at an urban tertiary care hospital between January 2002 to December 2017. Results: In 106 adolescents with PCOS who had OGTT results available, IGT was markedly pronounced in the ≥95th percentile BMI group (17 out of 72; 23.6%) compared with <95th percentile BMI group (4 out of 34; 11.7%). One patient with obesity met the criteria for type 2 diabetes. Patients with obesity had significantly higher homeostasis model assessment (HOMA-IR) and lower whole body insulin sensitivity index (WBISI) (p < 0.001) compared to patients without obesity. Free testosterone levels were also higher in patients with obesity (p< 0.03) and were significantly associated with HOMA-IR when controlling for body mass index (BMI). HbA1c did not demonstrate a strong ability to predict abnormal OGTT on receiver operating characteristic (ROC) curve analysis [Area under the curve (AUC) = 0.572, 95% CI: 0.428, 0.939]). Conclusions: In a study to assess glucose abnormalities in adolescents with PCOS, IGT was found to be markedly increased in patients with obesity, with abnormal glucose metabolism identified in over one-fifth of the patients. HbA1c alone may be a poor test to assess IGT and we recommend that adolescents diagnosed with PCOS and obesity undergo formal oral glucose tolerance testing.

Overview

CoChat Summary

TL;DR

In 106 adolescents with PCOS who underwent a 75-g OGTT, impaired glucose tolerance was more common in those with BMI ≥95th percentile (23.6%) than in those with BMI <95th percentile (11.7%). HbA1c alone poorly predicted an abnormal 2-hour OGTT, and the authors recommend formal OGTT for adolescents with PCOS and obesity.

Key findings

  • Abnormal 2-hour OGTT occurred in 21.6% of the total cohort; IGT was present in 17/72 (23.6%) of patients with BMI ≥95th percentile versus 4/34 (11.7%) of those with BMI <95th percentile. One patient with obesity met criteria for type 2 diabetes (2-hour glucose 273 mg/dl, HbA1c 8.1%).
  • Patients with obesity had higher insulin resistance and lower insulin sensitivity than patients without obesity: median HOMA-IR 4.02 vs 1.79 and median WBISI 2.00 vs 5.13 (p < 0.001 for both).
  • Free testosterone was higher in patients with obesity (median 7.90 vs 4.70 ng/dl, p = 0.026) and remained significantly associated with HOMA-IR when controlling for BMI (β = 0.151, 95% CI 0.033–0.269, p = 0.014).
  • HbA1c did not strongly predict abnormal 2-hour OGTT on ROC analysis (AUC = 0.572, 95% CI 0.428–0.939); IGT proportions did not differ significantly between normal and abnormal HbA1c groups (20.3% vs 30%, p = 0.310).

Methods

  • Retrospective cohort of female patients aged 11–18 years diagnosed with PCOS and evaluated at pediatric endocrinology clinics of an urban tertiary academic medical center between January 2002 and December 2017.
  • Of 286 patients identified with PCOS, 128 met initial inclusion criteria; 22 were excluded for metformin treatment, leaving 106 patients who underwent OGTT for final analysis. PCOS was defined by Androgen Excess Society 2009 criteria; obesity was BMI ≥95th percentile; OGTT categories used ADA criteria.
  • Data included OGTT glucose/insulin values, HbA1c, testosterone, BMI, and blood pressure. Analyses used median [IQR], Chi-squared/Fisher exact tests, Wilcoxon rank-sum tests, ROC curve for HbA1c predicting abnormal OGTT, and linear regressions for testosterone with HOMA-IR/WBISI, performed in R 3.5.3.

Limitations

  • Stated: the retrospective design did not allow systematic assessment of all patients, and the decision to perform glucose screening was provider dependent.
  • Stated: no comparative non-PCOS control group was included.
  • Stated/evident: only patients who had undergone formal OGTT were included, so the true prevalence of glucose abnormalities may be higher; HbA1c and OGTT results were both available in only 89/106 patients, and the single tertiary urban center may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12902-022-01098-0

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flowchart indicating study subjects
Fig. 1 Flowchart indicating study subjectsCC BY · PubMed Central
Fig. 2 Differences in biochemical characteristics between the < 95th percentile and ≥ 95th percentile groups for A 2 h glucose, B HOMA-IR and WBISI, and C free testosterone levels
Fig. 2 Differences in biochemical characteristics between the < 95th percentile and ≥ 95th percentile groups for A 2 h glucose, B HOMA-IR and WBISI, and C free testosterone levelsCC BY · PubMed Central
Fig. 3 ROC curve of HbA1c predicting abnormal OGTT
Fig. 3 ROC curve of HbA1c predicting abnormal OGTTCC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 3 Not valid · 6 Not checked · 25 Own results and interpretations

11 more claims

Create a free account to see all 40 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 28 references

Cited by

See all 9

Metadata

Authors
Gupta, J., Antal, Z., Mauer, E., Gerber, L. M., An, A., & Censani, M.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • Weill Cornell Medicine (US)
Corresponding author
Censani, Marisa
Venue
BMC Endocrine Disorders
Published
2022-07-16
Volume
22
Issue
1
Pages
180-180
ISSN
1472-6823 (ISSN-L)
OpenAlex
W4285587339
Cited by
9
References
28
Citations by year
2026: 3 · 2025: 4 · 2024: 1 · 2023: 1
FWCI
1.26
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Endocrine Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR002384)
  • National Center for Advancing Translational Sciences (TR002384)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
Keywords
polycystic ovary syndrome, adolescents, impaired glucose tolerance, type 2 diabetes, obesity, dysglycemia, oral glucose tolerance test, HbA1c, insulin resistance, HOMA-IR, free testosterone, body mass index
MeSH terms
Adolescent, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin Resistance, Obesity, Polycystic Ovary Syndrome, Retrospective Studies, Body Mass Index, Glucose Intolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dysglycemia screening with oral glucose tolerance test in adolescents with polycystic ovary syndrome and relationship with obesity. https://app.cochat.ai/papers/10.1186/s12902-022-01098-0
The paper
Gupta, J., Antal, Z., Mauer, E., Gerber, L. M., An, A., & Censani, M. (2022). Dysglycemia screening with oral glucose tolerance test in adolescents with polycystic ovary syndrome and relationship with obesity. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-022-01098-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.